Meeting
2017 ASCO Annual Meeting
A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).
Authors
Ji Zhu
Fudan University Shanghai Cancer Center, Shanghai, China
Ji Zhu , Xinchen Sun , Tao Zhang , Anwen Liu , Yuan Zhu , Jianhui Jia , Yaqun Zhu , Shisheng Tan , Juying Zhou , Chen Zhang , Xin Wang , Gang Cai , Bo Luo , Junxin Wu , Jialin Yang , Zhen Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02605265
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3632)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3632
Abstract #
TPS3632
Poster Bd #
248a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.
First Author: Ji Zhu
Poster
2019 ASCO Annual Meeting
A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).
First Author: Zhen Zhang
Poster
2023 ASCO Annual Meeting
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
First Author: Zhenyu Lin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe